CryoPort, Inc. $CYRX Stock Holdings Increased by Acadian Asset Management LLC

Key Points

• Acadian Asset Management LLC increased its stake in CryoPort, Inc. by 106.4% during the first quarter, owning approximately $2.91 million worth of shares.
• In recent insider transactions, CFO Robert Stefanovich sold 9,300 shares while Director Ramkumar Mandalam sold 40,728 shares, indicating significant changes in ownership among company executives.
• Analysts are optimistic about CryoPort, with several upgrades leading to a consensus price target of $12.00 and a majority rating of Buy or Strong Buy from multiple firms.

Acadian Asset Management LLC raised its holdings in CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 106.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 479,695 shares of the company's stock after purchasing an additional 247,288 shares during the quarter. Acadian Asset Management LLC owned about 0.96% of CryoPort worth $2,911,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. lifted its position in CryoPort by 148.7% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after acquiring an additional 2,120 shares during the period. Sierra Summit Advisors LLC raised its stake in shares of CryoPort by 5.0% during the first quarter. Sierra Summit Advisors LLC now owns 45,060 shares of the company's stock worth $274,000 after purchasing an additional 2,150 shares during the last quarter. MetLife Investment Management LLC raised its stake in shares of CryoPort by 13.8% during the first quarter. MetLife Investment Management LLC now owns 24,641 shares of the company's stock worth $150,000 after purchasing an additional 2,980 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of CryoPort by 1.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 370,302 shares of the company's stock worth $2,251,000 after purchasing an additional 5,207 shares during the last quarter. Finally, Graham Capital Management L.P. increased its stake in CryoPort by 24.9% in the 4th quarter. Graham Capital Management L.P. now owns 28,460 shares of the company's stock valued at $221,000 after buying an additional 5,667 shares during the period. Hedge funds and other institutional investors own 92.90% of the company's stock.

Insider Buying and Selling at CryoPort

In other news, CEO Jerrell Shelton sold 16,344 shares of the firm's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $7.06, for a total value of $115,388.64. Following the transaction, the chief executive officer directly owned 912,419 shares in the company, valued at approximately $6,441,678.14. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Robert Stefanovich sold 9,300 shares of the stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $8.67, for a total transaction of $80,631.00. Following the sale, the chief financial officer owned 207,213 shares in the company, valued at approximately $1,796,536.71. This trade represents a 4.30% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 109,693 shares of company stock valued at $870,021. Corporate insiders own 10.00% of the company's stock.

CryoPort Stock Down 0.8%

Shares of CYRX stock traded down $0.08 during trading hours on Friday, reaching $9.97. The company had a trading volume of 786,394 shares, compared to its average volume of 596,868. The company has a market capitalization of $499.20 million, a P/E ratio of 7.50 and a beta of 1.62. CryoPort, Inc. has a twelve month low of $4.58 and a twelve month high of $10.46. The stock's fifty day simple moving average is $8.41 and its 200 day simple moving average is $7.04. The company has a debt-to-equity ratio of 0.39, a quick ratio of 15.47 and a current ratio of 16.24.

CryoPort (NASDAQ:CYRX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.09). The business had revenue of $45.45 million for the quarter, compared to analyst estimates of $41.74 million. CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. CryoPort has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on CYRX shares. Stephens started coverage on shares of CryoPort in a research note on Tuesday, July 22nd. They issued an "overweight" rating and a $13.00 price objective on the stock. BTIG Research raised their price objective on shares of CryoPort from $10.00 to $15.00 and gave the company a "buy" rating in a research report on Thursday. Leerink Partnrs upgraded shares of CryoPort from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, August 6th. KeyCorp raised CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 target price for the company in a research note on Wednesday, August 6th. Finally, Leerink Partners raised CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 price objective on the stock in a report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $12.56.

CryoPort Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.